ArticleBMC pediatrics2026
A novel evaluation indicator for pediatric fulminant myocarditis: diagnostic and prognostic value of the HALP score.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPediatric fulminant myocarditis (FM) is characterized by a critical and rapidly progressive course. Current diagnostic approaches primarily rely on cardiac function and myocardial injury markers, which fail to comprehensively assess the associated systemic inflammation and immune dysregulation. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, a composite index integrating hemoglobin (Hb), albumin (Alb), lymphocyte count (Lym), and platelet count (Plt), offers a new perspective for evaluating the severity of pediatric fulminant myocarditis.
objectiveTo evaluate the diagnostic and prognostic utility of the HALP score in pediatric patients with fulminant myocarditis.
methodsThis retrospective study included 71 children with myocarditis (22 with FM, 49 with non-fulminant myocarditis [NFM]). The HALP score was calculated from admission laboratory parameters (Hb × Alb × Lym / Plt). Clinical manifestations, laboratory parameters, and echocardiographic findings were compared between groups. Diagnostic performance was assessed via receiver operating characteristic (ROC) curve analysis. Associations with clinical outcomes (Pediatric Intensive Care Unit [PICU] admission, mechanical ventilation, vasoactive drug use) were analyzed. Independent predictors of FM were identified using multivariate logistic regression.
resultsPatients in the FM group exhibited significantly higher rates of gallop rhythm (72.73% vs. 22.45%, P < 0.001), hepatomegaly (50.00% vs. 8.16%, P < 0.001) and dyspnea/tachypnea (31.82% vs. 12.24%, P = 0.049) compared to the NFM group. The median HALP score was significantly lower in the FM group compared to the NFM group (27.06 vs. 50.22, P = 0.005). The HALP score had an area under the ROC curve (AUC) of 0.724 for diagnosing FM, with an optimal cutoff of 36.07 (sensitivity 77.6%, specificity 68.2%). Based on this cutoff, children in the low-HALP group (< 36.07, n = 26) had significantly higher rates of mechanical ventilation (30.77% vs. 6.67%, P = 0.014), PICU admission (69.23% vs. 15.56%, P < 0.001), and vasoactive drug use (61.54% vs. 15.56%, P < 0.001) compared to the high-HALP group (≥ 36.07, n = 45). Multivariate analysis confirmed that a lower HALP score (OR = 0.946, 95% CI: 0.895–0.999, P = 0.047), along with elevated high-sensitivity troponin I (Hs-cTnI) (OR = 1.086, 95% CI: 1.019–1.158, P = 0.012) and reduced left ventricular ejection fraction (LVEF) (OR = 0.865, 95% CI: 0.783–0.956, P = 0.005), were independent risk factors for FM.
conclusionThe HALP score, a simple composite index derived from routine blood tests, demonstrates potential value for the diagnosis, severity stratification, and prognosis prediction of pediatric fulminant myocarditis. It complements conventional cardiac markers by reflecting systemic inflammation–immune status. Given the exploratory nature of this study, these findings warrant validation in larger prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.